UMMS Affiliation
Department of Medicine, Division of Hematology Oncology
Publication Date
2018-04-11
Document Type
Article
Disciplines
Hematology | Hemic and Lymphatic Diseases | Neoplasms | Nutritional and Metabolic Diseases | Oncology
Abstract
We present a case of a patient with cutaneous T-cell lymphoma started on bexarotene 300 mg/m(2) due to progressing disease. The patient experienced good clinical response, but unfortunately, she developed rapid and profound hypertriglyceridemia. Although hypertriglyceridemia occurs in high incidence with bexarotene therapy, management recommendations are scarce. Due to the rise in triglycerides, atorvastatin 10 mg daily was initiated in combination with fenofibrate 120 mg daily. Triglycerides continued to increase, so the patient was instructed to take atorvastatin 40 mg, fenofibrate 120 mg, and to hold bexarotene for 2 weeks. After the 2-week break, bexarotene was restarted at 150 mg/m(2).
Keywords
Bexarotene, Cutaneous T-cell lymphoma, Hypertriglyceridemia
Rights and Permissions
© 2018 The Author(s). This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
DOI of Published Version
10.1159/000488447
Source
Case Rep Oncol. 2018 Apr 11;11(1):234-238. doi: 10.1159/000488447. eCollection 2018 Jan-Apr. Link to article on publisher's site
Journal/Book/Conference Title
Case reports in oncology
Related Resources
PubMed ID
29805374
Repository Citation
Maminakis C, Whitman AC, Islam N. (2018). Bexarotene-Induced Hypertriglyceridemia: A Case Report. Open Access Publications by UMass Chan Authors. https://doi.org/10.1159/000488447. Retrieved from https://escholarship.umassmed.edu/oapubs/3456
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Included in
Hematology Commons, Hemic and Lymphatic Diseases Commons, Neoplasms Commons, Nutritional and Metabolic Diseases Commons, Oncology Commons